Associated Papers
How does the novel T315L mutation of breakpoint cluster region-abelson (BCR-ABL) kinase confer resistance to ponatinib: a comparative molecular dynamics simulation study.
Zhang H et al.
Journal of Biomolecular Structure & Dynamics, 2020
HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia.
Park JH et al.
Leukemia, 2019
30555164 (PubMed )
Supplement: 41375_2018_321_MOESM1_ESM.docx
Modeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug design.
Panigrahi S et al.
Plos One, 2012
Select a paper to view details